Author:
Jiang Dawei,Im Hyung-Jun,Sun Haiyan,Valdovinos Hector F.,England Christopher G.,Ehlerding Emily B.,Nickles Robert J.,Lee Dong Soo,Cho Steve Y.,Huang Peng,Cai Weibo
Funder
National Institutes of Health
National Cancer Institute
American Cancer Society
National Science Foundation of China
Publisher
Springer Science and Business Media LLC
Subject
Radiology, Nuclear Medicine and imaging,General Medicine,Radiology, Nuclear Medicine and imaging,General Medicine
Reference32 articles.
1. Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, Kinney R, et al. Overexpression of Her-2/Neu is associated with poor survival in advanced epithelial ovarian-cancer. Cancer Res. 1990;50:4087–91.
2. Bartlett JM, Langdon SP, Simpson BJ, Stewart M, Katsaros D, Sismondi P, et al. The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. Br J Cancer. 1996;73:301–6. doi:
10.1038/bjc.1996.53
.
3. Tuefferd M, Couturier J, Penault-Llorca F, Vincent-Salomon A, Broet P, Guastalla JP, et al. HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients. PLoS One. 2007;2:e1138. doi:
10.1371/journal.pone.0001138
.
4. Magnifico A, Albano L, Campaner S, Delia D, Castiglioni F, Gasparini P, et al. Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab. Clin Cancer Res. 2009;15:2010–21. doi:
10.1158/1078-0432.CCR-08-1327
.
5. Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol. 2011;9:16–32. doi:
10.1038/nrclinonc.2011.177
.
Cited by
29 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献